Recently, however, the Food and Drug Administration approved gene therapy for the treatment of RPE65-related Leber congenital amaurosis in patients with RPE65 mutations after gene replacement demonstrated improvement of functional vision [15]. Here, RPE65 is linked to Leber congenital amaurosis.